Bayer BAYRY announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) ...

The FDA has approved Roche’s Susvimo (ranibizumab injection) 100 mg/mL for treating patients with diabetic retinopathy (DR).

The FDA approved Susvimo 100 mg/mL to treat diabetic retinopathy, according to a press release from Genentech.The approval was supported by positive 1-year data from the phase 3 Pavilion study in ...

Basel: Roche has received approval from the US Food and Drug Administration (FDA) for Susvimo (ranibizumab injection) 100 ...

A single intravitreal injection of UBX1325 (foselutoclax), a novel senolytic small molecule inhibitor, had a tolerable safety profile and "trends suggestive of potential efficacy" in patients with ...

Susvimo is also approved to treat diabetic macular edema and age-related macular degeneration, and the medication, ...

Ashvattha Therapeutics reveals promising phase 2 results for migaldendranib, showcasing significant improvements in retinal disease treatment and reduced injection burden.

In this Healio Video Perspective, Michael A. Singer, MD, discusses promising results for migaldendranib for the treatment of ...

Biotechnology company Optigo Biotherapeutics received the People’s Choice Award at the 2025 Eyecelerator meeting for the ...

Results of a phase IIb trial comparing UBX1325 to anti-VEGF therapy are expected later this year. A single intravitreal injection of UBX1325 (foselutoclax), a novel senolytic small molecule ...